SOPHARMA TRADING AD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.65 BGN | +1.80% |
|
+1.80% | -5.83% |
| Mar. 15 | Sopharma Trading AD(BUL:SFT) dropped from SOFIX Index | CI |
| Feb. 29 | Sopharma Trading AD Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 230.3 | 193.7 | 190.2 | 179.9 | 205.7 | 205.7 |
| Enterprise Value (EV) 1 | 417.1 | 406.9 | 476 | 438.9 | 452.4 | 444 |
| P/E ratio | 26.4 x | 22.2 x | 16.1 x | 22.5 x | 23.2 x | 6.85 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 0.26 x | 0.2 x | 0.16 x | 0.13 x | 0.14 x | 0.12 x |
| EV / Revenue | 0.47 x | 0.42 x | 0.41 x | 0.33 x | 0.31 x | 0.26 x |
| EV / EBITDA | 22.2 x | 15.7 x | 18.5 x | 15.5 x | 8.66 x | 6.04 x |
| EV / FCF | -15.8 x | -55.9 x | 2,418 x | 12.3 x | 11.6 x | 10.4 x |
| FCF Yield | -6.35% | -1.79% | 0.04% | 8.15% | 8.64% | 9.59% |
| Price to Book | 3.67 x | 2.55 x | 2.46 x | 2.12 x | 2.17 x | 1.66 x |
| Nbr of stocks (in thousands) | 32,905 | 34,276 | 34,276 | 34,276 | 34,276 | 34,276 |
| Reference price 2 | 7.000 | 5.650 | 5.550 | 5.250 | 6.000 | 6.000 |
| Announcement Date | 5/10/19 | 3/2/20 | 2/26/21 | 2/28/22 | 3/1/23 | 2/29/24 |
1BGN in Million2BGN
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 887.8 | 958.7 | 1,156 | 1,336 | 1,478 | 1,678 |
| EBITDA 1 | 18.82 | 25.92 | 25.7 | 28.37 | 52.25 | 73.5 |
| EBIT 1 | 10.99 | 11.88 | 17.09 | 16.34 | 39.57 | 44.68 |
| Operating Margin | 1.24% | 1.24% | 1.48% | 1.22% | 2.68% | 2.66% |
| Earnings before Tax (EBT) 1 | 10.19 | 10.52 | 13.81 | 9.805 | 12.55 | 34.18 |
| Net income 1 | 8.717 | 8.718 | 11.79 | 7.991 | 8.859 | 30.03 |
| Net margin | 0.98% | 0.91% | 1.02% | 0.6% | 0.6% | 1.79% |
| EPS 2 | 0.2649 | 0.2543 | 0.3439 | 0.2331 | 0.2585 | 0.8761 |
| Free Cash Flow 1 | -26.48 | -7.275 | 0.1969 | 35.78 | 39.11 | 42.59 |
| FCF margin | -2.98% | -0.76% | 0.02% | 2.68% | 2.65% | 2.54% |
| FCF Conversion (EBITDA) | - | - | 0.77% | 126.12% | 74.84% | 57.94% |
| FCF Conversion (Net income) | - | - | 1.67% | 447.81% | 441.42% | 141.82% |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 5/10/19 | 3/2/20 | 2/26/21 | 2/28/22 | 3/1/23 | 2/29/24 |
1BGN in Million2BGN
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | 187 | 213 | 286 | 259 | 247 | 238 |
| Net Cash position 1 | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | 9.925 x | 8.225 x | 11.12 x | 9.125 x | 4.722 x | 3.243 x |
| Free Cash Flow 1 | -26.5 | -7.28 | 0.2 | 35.8 | 39.1 | 42.6 |
| ROE (net income / shareholders' equity) | 12% | 12% | 15.4% | 9.88% | 9.87% | 27.5% |
| ROA (Net income/ Total Assets) | 1.68% | 1.65% | 1.94% | 1.71% | 4.28% | 4.6% |
| Assets 1 | 520 | 528.8 | 606.2 | 468.7 | 206.8 | 652.2 |
| Book Value Per Share 2 | 1.910 | 2.210 | 2.260 | 2.480 | 2.760 | 3.620 |
| Cash Flow per Share 2 | 0.1600 | 0.2200 | 0.2100 | 0.3400 | 0.2000 | 0.3800 |
| Capex 1 | 10.1 | 21.3 | 8.53 | 7.53 | 5.75 | 10.3 |
| Capex / Sales | 1.13% | 2.22% | 0.74% | 0.56% | 0.39% | 0.62% |
| Announcement Date | 5/10/19 | 3/2/20 | 2/26/21 | 2/28/22 | 3/1/23 | 2/29/24 |
1BGN in Million2BGN
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -5.83% | 106M | |
| +19.62% | 43.34B | |
| +20.44% | 21.96B | |
| +10.86% | 14.09B | |
| +13.07% | 13.64B | |
| +37.46% | 11.43B | |
| -8.59% | 6.86B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +8.46% | 5.22B |
- Stock Market
- Equities
- SFT Stock
- Financials Sopharma Trading AD
